Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry

Clinical Transplantation

Volumn 30, Issue 12, 2016, Pages 1570-1577

  Stepanova, Maria ^a,b   Locklear, Trevor ^c   Rafiq, Nila ^a,c   Mishra, Alita ^a,c   Venkatesan, Chapy ^c   Younossi, Zobair M ^a,c  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b Center for Outcomes Research in Liver Diseases   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

extended criteria donor; graft loss; heart transplant; hepatitis C; mortality; outcomes; SRTR

Indexed keywords

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE REGISTRY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HEART ARREST; HEART GRAFT; HEPATITIS C; HUMAN; HYPERTENSION; KIDNEY FAILURE; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEPTICEMIA; SURGICAL MORTALITY; TREATMENT OUTCOME; UNITED STATES; AGED; CASE CONTROL STUDY; CHRONIC HEPATITIS C; COMPLICATION; HEART FAILURE; HEART TRANSPLANTATION; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGISTER; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART TRANSPLANTATION; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84999421215     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12859     Document Type: Article

References (38)

1. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;122:173–183.
2. Carbone M, Mutimer D, Neuberger J. Hepatitis C virus and nonliver solid organ transplantation. Transplantation. 2013;95:779–786.
3. Choy-Shan A, Berezovskaya S, Zinn A, Sedlis SP, Bini EJ. Nonischemic cardiomyopathy related to pegylated interferon and ribavirin. Eur J Gastroenterol Hepatol. 2009;21:1438–1440.
4. LaFleur J, Hoop R, Korner E, et al. Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C. Gastroenterol Nurs 2015;38:417. e428.
5. Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol. 2015;8:298–312.
6. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35:1–23.
7. Belga S, Doucette KE. Hepatitis C in non-hepatic solid organ transplant candidates and recipients: a new horizon. World J Gastroenterol. 2016;22:1650–1663.
8. Kim EY, Ko HH, Yoshida EM. A concise review of hepatitis C in heart and lung transplantation. Can J Gastroenterol. 2011;25:445–448.
9. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293–300.
10. Fouad YM, Yehia R. Hepato-cardiac disorders. World J Hepatol. 2014;6:41–54.
11. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37:647–652.
12. Petta S, Maida M, Macaluso FS, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 2016;150:145–155. e4.
13. Mahajan R, Xing J, Liu SJ, et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis. 2014;58:1055–1061.
14. Lin MH, Chou NK, Chi NH, et al. The outcome of heart transplantation in hepatitis C-positive recipients. Transplant Proc. 2012;44:890–893.
15. Fong TL, Hou L, Hutchinson IV, Cicciarelli JC, Cho YW. Impact of hepatitis C infection on outcomes after heart transplantation. Transplantation. 2009;88:1137–1141.
16. Cano O, Almenar L, Martínez-Dolz L, et al. Course of patients with chronic hepatitis C virus infection undergoing heart transplantation. Transplant Proc. 2007;39:2353–2354.
17. Sekar B, Newton PJ, Williams SG, Shaw SM. Should we consider patients with coexistent hepatitis B or C infection for orthotopic heart transplantation? J Transplant. 2013;2013:748578.
18. Lee I, Localio R, Brensinger CM, et al. Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant. 2011;30:1266–1274.
19. Kumar S, Deo SV, Altarabsheh SE, et al. Effect of hepatitis C positivity on survival in adult patients undergoing heart transplantation (from the United Network for Organ Sharing Database). Am J Cardiol. 2016;118:132–137.
20. Fagiuoli S, Minniti F, Pevere S, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant. 2001;20:718–724.
21. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
22. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312:353–361.
23. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–713.
24. Milazzo L, Lai A, Calvi E, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med. 2016; doi:10.1111/hiv.12429.
25. Bonacci M, Lens S, Mariño Z, Forns X. Challenges in special populations: HIV/HCV coinfection, liver transplantation and patients with end-stage renal disease. Dig Dis. 2016;34:317–326.
26. Lin MV, Sise ME, Pavlakis M, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection. PLoS One. 2016;11:e0158431.
27. Calabrese LH, Cacoub PP. For patients with rheumatic disease and hepatitis C infection: the end of interferon. RMD Open. 2015;1:e000008.
28. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485–1494.
29. Nguyen NH, Yee BE, Chang C, et al. Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. BMJ Open Gastroenterol. 2016;3:e000066.
30. Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol. 2016;8:69–73.
31. Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588–1595.
32. Beinhardt S, Al Zoairy R, Ferenci P, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int. 2016; doi:10.1111/tri.12799.
33. Trakroo S, Qureshi K. Successful treatment of chronic hepatitis C infection with direct-acting antivirals in a heart transplant recipient: a case report. Transplant Proc. 2015;47:2295–2297.
34. Doucette K, Sumner S, Weinkauf J. Treatment of hepatitis C in a lung transplant recipient with sofosbuvir and daclatasvir. J Heart Lung Transplant 2016;35:840–841.
35. Yamani MH, Taylor DO. Heart Transplantation. Cleveland Clinic, Center for Continuing Education; August 2010. http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/heart-transplantation/. Accessed August 18, 2016.
36. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530. e1.
37. Srivastava AV, Hrobowski T, Krese L, et al. High rates of false-positive hepatitis C antibody tests can occur after left ventricular assist device implantation. ASAIO J. 2013;59:660–661.
38. Heinrichs A, Antoine M, Steensels D, Montesinos I, Delforge ML. HCV false positive immunoassays in patients with LVAD: a potential trap! J Clin Virol. 2016;10:44–46.